Similarly, the concomitant use of erlotinib and of the VEGF-targeting monoclonal antibody bevacizumab in a phase II trial on relapsed glioblastoma patients did not improve progression-free survival when compared to patients treated with bevacizumab as a monotherapy [58,59]. This evidence concerns the gene VEGFA and glioblastoma.